Compare

Krystal Biotech, Inc. vs Immunocore Holdings plc vs Tarsus Pharmaceuticals, Inc. vs Twist Bioscience Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearKrystal Biotech, Inc.
KRYS
Immunocore Holdings plc
IMCR
Tarsus Pharmaceuticals, Inc.
TARS
Twist Bioscience Corp
TWST
Year ended2025-12-312025-12-312025-12-312026-09-30
Revenue$389.13M$400.02M$451.36M$459.43M
Revenue growth (YoY)+33.9%+29.0%+146.7%+22.0%
Gross marginn/an/an/a52.4% (computed)
Operating margin41.5%-11.3%-15.7%-30.4%
Net margin52.6%-8.9%-14.7%-28.3%
Net income$204.83M-$35.51M-$66.42M-$130.20M
EPS (Diluted)$6.84-$0.71-$1.59-$2.08
Operating cash flow$200.87M-$10.71M-$12.45M-$41.43M
Free cash flow$188.91M-$15.05M-$22.31M-$89.01M
Cash & equivalents$496.30M$467.71M$183.64M$533.99M
Total assets$1.33B$1.07B$562.16M$1.12B
Total liabilities$114.23M$686.24M$218.73M$233.79M
Shareholders' equity$1.22B$381.03M$343.43M$888.02M
Return on year-end equity16.8%-9.3%-19.3%-14.7%
Shares outstanding29.19M50.69M42.55M67.81M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearKrystal Biotech, Inc.Immunocore Holdings plcTarsus Pharmaceuticals, Inc.Twist Bioscience Corp
Latest$389.13M
Ended 2025-12-31
$400.02M
Ended 2025-12-31
$451.36M
Ended 2025-12-31
$459.43M
Ended 2026-09-30
1 year earlier$290.51M
Ended 2024-12-31
$310.20M
Ended 2024-12-31
$182.95M
Ended 2024-12-31
$376.57M
Ended 2025-09-30
2 years earlier$50.70M
Ended 2023-12-31
$249.43M
Ended 2023-12-31
$17.45M
Ended 2023-12-31
$312.97M
Ended 2024-09-30
3 years earlier$0
Ended 2022-12-31
$174.36M
Ended 2022-12-31
$25.82M
Ended 2022-12-31
$245.11M
Ended 2023-09-30
4 years earlier$0
Ended 2021-12-31
$36.48M
Ended 2021-12-31
$57.03M
Ended 2021-12-31
$203.56M
Ended 2022-09-30